Get our Free Patent Expiration Newsletter

Serving leading biopharmaceutical companies globally:

Moodys
AstraZeneca
Johnson and Johnson
Harvard Business School
McKesson
Baxter

Last Updated: January 22, 2020

DrugPatentWatch Database Preview

CLINICAL TRIALS PROFILE FOR GLASDEGIB

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

All Clinical Trials for Glasdegib

Trial ID Title Status Sponsor Phase Start Date Summary
NCT02226172 Single-Agent Glasdegib In Patients With Myelofibrosis Previously Treated With Ruxolitinib Recruiting Pfizer Phase 2 2014-10-01 A lead-in cohort of ~20 patients with primary or secondary myelofibrosis previously treated with 1 or more Janus kinase inhibitors enrolled to single-agent glasdegib to evaluate safety and tolerability. Following the lead-in, a phase 2, double blind, 2-arm study, randomized 2:1 to oral single-agent glasdegib versus placebo in 201 patients resistant or intolerant to ruxolitinib.
NCT02367456 A Combination Study of PF-04449913 (Glasdegib) and Azacitidine In 1st Line MDS, AML and CMML Patients Recruiting Pfizer Phase 1 2015-04-01 This multi center randomized (1:1), double blind, placebo controlled Phase 1b/2 study is designed to compare the safety, efficacy, pharmacokinetics (PK), and pharmacodynamics (PD) of PF 04449913 or placebo when combined with azacitidine in patients with previously untreated Intermediate 2 or High Risk Myelodysplastic Syndrome (MDS), Acute Myeloid Leukemia (AML) with 20-30% blasts and multi lineage dysplasia, and Chronic Myelomonocytic Leukemia (CMML). This clinical study includes two components: (a) a Phase 1b safety lead in and (b) a randomized Phase 2.
NCT02430545 Understanding The Effect Of A Strong CYP3A4 Inducer On Glasdegib Pharmacokinetics Completed Pfizer Phase 1 2015-05-01 The study also aims to determine the effect of a strong enzyme (CYP3A4) inducer-rifampin- on drug exposure of Glasdegib. This study will be conducted in healthy subjects given a single dose of glasdegib in each period.
>Trial ID >Title >Status >Phase >Start Date >Summary

Clinical Trial Conditions for Glasdegib

Condition Name

Condition Name for Glasdegib
Intervention Trials
Acute Myeloid Leukemia 3
Healthy Volunteers 3
Healthy Volunteer Study 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Condition MeSH

Condition MeSH for Glasdegib
Intervention Trials
Leukemia, Myeloid, Acute 4
Leukemia, Myeloid 4
Leukemia 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Locations for Glasdegib

Trials by Country

Trials by Country for Glasdegib
Location Trials
United States 33
Japan 13
Spain 4
Belgium 3
Korea, Republic of 3
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Trials by US State

Trials by US State for Glasdegib
Location Trials
Connecticut 5
Utah 3
New York 3
California 3
Maryland 2
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Progress for Glasdegib

Clinical Trial Phase

Clinical Trial Phase for Glasdegib
Clinical Trial Phase Trials
Phase 3 4
Phase 2 2
Phase 1/Phase 2 3
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Status

Clinical Trial Status for Glasdegib
Clinical Trial Phase Trials
Not yet recruiting 8
Recruiting 6
Completed 2
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Clinical Trial Sponsors for Glasdegib

Sponsor Name

Sponsor Name for Glasdegib
Sponsor Trials
Pfizer 10
Plateforme labellisée Inca – Institut Bergonié, Bordeaux 1
Fred Hutchinson Cancer Research Center 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Sponsor Type

Sponsor Type for Glasdegib
Sponsor Trials
Other 13
Industry 10
NIH 1
[disabled in preview] 0
This preview shows a limited data set
Subscribe for full access, or try a Trial

Export unavailable in trial.
Subscribe for complete access.

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

McKinsey
Baxter
Medtronic
Boehringer Ingelheim
Mallinckrodt
Moodys

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.